GB9107513D0 - Pyrazolopyridine compound and processes for preparation thereof - Google Patents

Pyrazolopyridine compound and processes for preparation thereof

Info

Publication number
GB9107513D0
GB9107513D0 GB919107513A GB9107513A GB9107513D0 GB 9107513 D0 GB9107513 D0 GB 9107513D0 GB 919107513 A GB919107513 A GB 919107513A GB 9107513 A GB9107513 A GB 9107513A GB 9107513 D0 GB9107513 D0 GB 9107513D0
Authority
GB
United Kingdom
Prior art keywords
processes
preparation
pyrazolopyridine compound
pharmaceutically acceptable
pyrazolopyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB919107513A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB919107513A priority Critical patent/GB9107513D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of GB9107513D0 publication Critical patent/GB9107513D0/en
Priority to AU13988/92A priority patent/AU653007B2/en
Priority to TW081102547A priority patent/TW205550B/zh
Priority to IE108692A priority patent/IE921086A1/en
Priority to FI921522A priority patent/FI100969B/fi
Priority to SG1996005302A priority patent/SG43917A1/en
Priority to ES92106028T priority patent/ES2095976T3/es
Priority to EP92106028A priority patent/EP0516941B1/en
Priority to DE69215965T priority patent/DE69215965T2/de
Priority to AT92106028T priority patent/ATE146473T1/de
Priority to DK92106028.1T priority patent/DK0516941T3/da
Priority to HU9201213A priority patent/HU214871B/hu
Priority to SU5011507/04A priority patent/RU2069662C1/ru
Priority to CA002065644A priority patent/CA2065644C/en
Priority to JP4088735A priority patent/JP2546470B2/ja
Priority to IL10154492A priority patent/IL101544A/en
Priority to CNB971253781A priority patent/CN100508975C/zh
Priority to NO19921413A priority patent/NO300271B1/no
Priority to CN92103372A priority patent/CN1041203C/zh
Priority to US07/866,215 priority patent/US5234930A/en
Priority to KR1019920005893A priority patent/KR100248700B1/ko
Priority to MX9201672A priority patent/MX9201672A/es
Priority to UA93002532A priority patent/UA27252C2/uk
Priority to HU95P/P00354P priority patent/HU211680A9/hu
Priority to JP7298193A priority patent/JP2903040B2/ja
Priority to GR960403475T priority patent/GR3022113T3/el
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Developing Agents For Electrophotography (AREA)
GB919107513A 1991-04-10 1991-04-10 Pyrazolopyridine compound and processes for preparation thereof Pending GB9107513D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB919107513A GB9107513D0 (en) 1991-04-10 1991-04-10 Pyrazolopyridine compound and processes for preparation thereof
AU13988/92A AU653007B2 (en) 1991-04-10 1992-04-02 Pyrazolopyridine compound and processes for preparation thereof
TW081102547A TW205550B (https=) 1991-04-10 1992-04-02
IE108692A IE921086A1 (en) 1991-04-10 1992-04-03 Pyrazolopyridine compound and processes for preparation¹thereof
FI921522A FI100969B (fi) 1991-04-10 1992-04-07 Menetelmä valmistaa terapeuttisesti aktiivista pyratsolo£1,5-a|pyridii niyhdistettä
SG1996005302A SG43917A1 (en) 1991-04-10 1992-04-08 Pyrazolopyridine compound and processes for preparation thereof
DK92106028.1T DK0516941T3 (da) 1991-04-10 1992-04-08 Pyrazolopyridinforbindelser og fremgangsmåder til fremstilling deraf
ES92106028T ES2095976T3 (es) 1991-04-10 1992-04-08 Compuestos de pirazolopiridina y procedimiento para su preparacion.
EP92106028A EP0516941B1 (en) 1991-04-10 1992-04-08 Pyrazolopyridine compounds and processes for preparation thereof
DE69215965T DE69215965T2 (de) 1991-04-10 1992-04-08 Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
AT92106028T ATE146473T1 (de) 1991-04-10 1992-04-08 Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
KR1019920005893A KR100248700B1 (ko) 1991-04-10 1992-04-09 피라졸로피리딘 화합물 및 이의 제조 방법
CN92103372A CN1041203C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的制备方法
HU9201213A HU214871B (hu) 1991-04-10 1992-04-09 Eljárás pirazol-piridin-származékok előállítására
CA002065644A CA2065644C (en) 1991-04-10 1992-04-09 Pyrazolopyridine compound and processes for preparation thereof
JP4088735A JP2546470B2 (ja) 1991-04-10 1992-04-09 ピラゾロピリジン化合物およびその製造方法
IL10154492A IL101544A (en) 1991-04-10 1992-04-09 2-aryl-3-(substituted piperidino) carbonylalkenyl pyrazolo [1,5-a] pyridines processes for the preparation thereof and pharmaceutical compositions containing the same
CNB971253781A CN100508975C (zh) 1991-04-10 1992-04-09 吡唑并吡啶化合物的用途
NO19921413A NO300271B1 (no) 1991-04-10 1992-04-09 Pyrazolopyridin-forbindelser og farmasoytiske preparater inneholdende disse
SU5011507/04A RU2069662C1 (ru) 1991-04-10 1992-04-09 Производные пиразоло [1,5-а] пиридина, или их фармацевтически приемлемые соли и способ их получения
US07/866,215 US5234930A (en) 1991-04-10 1992-04-09 Pyrazolopyridine compounds which have useful pharmaceutical utility
MX9201672A MX9201672A (es) 1991-04-10 1992-04-10 Compuesto de pirazol piridina y procedimiento para la preparacion de los mismos.
UA93002532A UA27252C2 (uk) 1991-04-10 1993-06-18 Похідні піразоло[1,5-а]піридину, які є антагоністами аденозину, та спосіб їх отримання
HU95P/P00354P HU211680A9 (en) 1991-04-10 1995-06-22 Pyrazolopyridine compounds which have useful pharmaceutical utility
JP7298193A JP2903040B2 (ja) 1991-04-10 1995-11-16 ピラゾロピリジン化合物の用途
GR960403475T GR3022113T3 (en) 1991-04-10 1996-12-19 Pyrazolopyridine compounds and processes for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919107513A GB9107513D0 (en) 1991-04-10 1991-04-10 Pyrazolopyridine compound and processes for preparation thereof

Publications (1)

Publication Number Publication Date
GB9107513D0 true GB9107513D0 (en) 1991-05-29

Family

ID=10692949

Family Applications (1)

Application Number Title Priority Date Filing Date
GB919107513A Pending GB9107513D0 (en) 1991-04-10 1991-04-10 Pyrazolopyridine compound and processes for preparation thereof

Country Status (23)

Country Link
US (1) US5234930A (https=)
EP (1) EP0516941B1 (https=)
JP (2) JP2546470B2 (https=)
KR (1) KR100248700B1 (https=)
CN (2) CN1041203C (https=)
AT (1) ATE146473T1 (https=)
AU (1) AU653007B2 (https=)
CA (1) CA2065644C (https=)
DE (1) DE69215965T2 (https=)
DK (1) DK0516941T3 (https=)
ES (1) ES2095976T3 (https=)
FI (1) FI100969B (https=)
GB (1) GB9107513D0 (https=)
GR (1) GR3022113T3 (https=)
HU (2) HU214871B (https=)
IE (1) IE921086A1 (https=)
IL (1) IL101544A (https=)
MX (1) MX9201672A (https=)
NO (1) NO300271B1 (https=)
RU (1) RU2069662C1 (https=)
SG (1) SG43917A1 (https=)
TW (1) TW205550B (https=)
UA (1) UA27252C2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
CN1046724C (zh) * 1993-12-29 1999-11-24 藤泽药品工业株式会社 吡唑并吡啶化合物、含有它们的药物组合物、及其制法与用途
WO1997040047A1 (en) * 1996-04-25 1997-10-30 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998041237A1 (en) * 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for hyperphosphatemia
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
ES2273487T3 (es) * 1998-06-01 2007-05-01 Astellas Pharma Inc. Antagonistas a1 de adenosina contra la esterilidad masculina.
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
JP2004515550A (ja) * 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
WO2002072581A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
WO2002078700A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002078701A1 (en) * 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
ES2266487T3 (es) 2001-04-10 2007-03-01 Smithkline Beecham Corporation Compuestos de pirazolopirina antivirales.
ATE296826T1 (de) * 2001-04-27 2005-06-15 Smithkline Beecham Corp Pyrazolo(1,5)pyridinderivate
AUPR548601A0 (en) * 2001-06-06 2001-06-28 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazinecompound and pharmaceutical use thereof
ATE337316T1 (de) * 2001-06-21 2006-09-15 Smithkline Beecham Corp Imidazo 1,2-aöpyridin-derivate zur prophylaxe und behandlung von herpes-infektionen
US20040214834A1 (en) * 2001-09-07 2004-10-28 Kristjan Gudmunsson Pyrazolo-pyridines for the treatment of herpes infections
EP1432712B1 (en) * 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
JP2005516916A (ja) * 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
RU2008152776A (ru) * 2006-06-06 2010-07-20 Эвиджен Инк. (Us) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof

Also Published As

Publication number Publication date
FI100969B (fi) 1998-03-31
HU211680A9 (en) 1995-12-28
SG43917A1 (en) 1997-11-14
HU214871B (hu) 1998-07-28
DE69215965D1 (de) 1997-01-30
NO921413D0 (no) 1992-04-09
CN1041203C (zh) 1998-12-16
CN1205205A (zh) 1999-01-20
ES2095976T3 (es) 1997-03-01
JP2546470B2 (ja) 1996-10-23
JPH05112566A (ja) 1993-05-07
KR920019787A (ko) 1992-11-20
DE69215965T2 (de) 1997-04-10
NO921413L (no) 1992-10-12
JPH08208650A (ja) 1996-08-13
AU653007B2 (en) 1994-09-15
CN100508975C (zh) 2009-07-08
TW205550B (https=) 1993-05-11
JP2903040B2 (ja) 1999-06-07
KR100248700B1 (ko) 2000-08-01
HUT61300A (en) 1992-12-28
CA2065644C (en) 2002-12-03
HU9201213D0 (en) 1992-07-28
IL101544A (en) 1996-06-18
UA27252C2 (uk) 2000-08-15
MX9201672A (es) 1992-10-01
AU1398892A (en) 1992-10-15
FI921522L (fi) 1992-10-11
CN1067427A (zh) 1992-12-30
IE921086A1 (en) 1992-10-21
IL101544A0 (en) 1992-12-30
EP0516941B1 (en) 1996-12-18
GR3022113T3 (en) 1997-03-31
EP0516941A1 (en) 1992-12-09
NO300271B1 (no) 1997-05-05
DK0516941T3 (da) 1997-01-06
US5234930A (en) 1993-08-10
CA2065644A1 (en) 1992-10-11
FI921522A0 (fi) 1992-04-07
RU2069662C1 (ru) 1996-11-27
ATE146473T1 (de) 1997-01-15

Similar Documents

Publication Publication Date Title
SG43917A1 (en) Pyrazolopyridine compound and processes for preparation thereof
DK0379979T3 (https=)
GB9015764D0 (en) Pyrazolopyridine compound and processes for preparation thereof
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
ZA928876B (en) Thiazole derivatives.
ZA912589B (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
ES2061579T3 (es) Compuestos cefem y procedimientos para su preparacion.